Pacira BioSciences, Inc. (PCRX)


Stock Price Forecast

April 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Pacira BioSciences, Inc. chart...

About the Company

We do not have any company description for Pacira BioSciences, Inc. at the moment.

Sector

Life Sciences

Industry

Pharmaceutical Preparations

Employees

778

Exchange

Nasdaq

$122M

Total Revenue

778

Employees

$1B

Market Capitalization

37.98

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PCRX News

Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag

1mon ago, source: Hosted on MSN

Pacira BioSciences, Inc. PCRX announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to PCRX-201 (enekinragene inzadenovec), the company’s novel ...

Commit To Purchase Pacira BioSciences At $15, Earn 12.5% Annualized Using Options

15d ago, source: Nasdaq

Investors considering a purchase of Pacira BioSciences Inc (Symbol: PCRX) shares, but cautious about paying the going market price of $29.22/share, might benefit from considering selling puts ...

Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results

1mon ago, source: Business Insider

Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported ...

Pacira BioSciences Inc PCRX

15d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Oversold Conditions For Pacira BioSciences (PCRX)

4d ago, source: Nasdaq

In trading on Monday, shares of Pacira BioSciences Inc (Symbol: PCRX) entered into oversold territory, hitting an RSI reading of 29.3, after changing hands as low as $25.84 per share. By ...

Navigating 4 Analyst Ratings For Pacira BioSciences

1mon ago, source: Benzinga.com

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients.

Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference

1mon ago, source: Yahoo Finance

TAMPA, Fla., March 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays 26 th Annual Global ...

Pacira BioSciences Inc. Registered Shares DL-,001 Aktie

22d ago, source: Finanzen100

Bitte entschuldigen Sie den Fehler. Sollte dieser Fehler erneut auftreten, kontaktieren Sie bitte unseren Kundeservice per E-Mail.

Pacira BioSciences Inc PCRX

15d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pacira BioSciences Inc.

8d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Pacira BioSciences Inc.

3mon ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...